Federal regulators will no longer require patients to provide blood tests before receiving the drug from pharmacies.
Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...
Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...
The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is ...
Depression risk lower with GLP-1 receptor agonists versus DPP-4 inhibitors in seniors, study reveals
For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...
A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...
St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...
The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
6d
GlobalData on MSNSupernus’s stock sinks after depression drug fails trialSupernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results